MARLBOROUGH, Mass. and WASHINGTON, Oct. 30, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the results of the primary endpoint of the ACURATE IDE clinical trial, which evaluated the ACURATE neo2™ Aortic Valve System in the treatment of patients with severe, symptomatic aortic stenosis at low, intermediate, high and extreme risk of open-heart surgery. The data were presented as a late-breaking clinical trial at Transcatheter Cardiovascular Therapeutics® (TCT®) 2024, the annual ...

Key TakeawaysBoston Scientific shares fell Wednesday as its third-quarter profit missed estimates.The medical device maker's adjusted earnings per share and revenue were more than expected, as sales of its cardiovascular products surged.Boston Scientific gave a mixed updated full-year forecast. Boston Scientific (BSX) shares fell Wednesday when the medical equipment manufacturer's third-quarter profit fell and its GAAP earnings per share (EPS) came in short of its guidance. The company reported net income d ...

Boston Scientific Corporation (BSX) posted adjusted earnings per share (EPS) of 63 cents for the third quarter of 2024, up 26% from the year-ago figure. The figure beat the Zacks Consensus Estimate by 8.6% and also exceeded the company’s adjusted earnings per share guidance range of 57-59 cents per share.The quarter’s adjustments included certain amortization expenses, acquisition/divestitures-related net charges, and restructuring and restructuring-related charges, among others.Reported EPS for the third q ...

Boston Scientific Corporation (NYSE:BSX) Q3 2024 Earnings Conference Call October 23, 2024 8:00 AM ET Company Participants Jonathan Monson - Senior Vice President, Investor Relations Michael Mahoney - Chairman and Chief Executive Officer Daniel Brennan - Executive Vice President and Chief Financial Officer Kenneth Stein - Senior Vice President, Global Chief Medical Officer Conference Call Participants Robert Marcus - JPMorgan Joanne Wuensch - Citigroup Inc. Lawrence Biegelsen - Wells Fargo Securities Freder ...

For the quarter ended September 2024, Boston Scientific (BSX) reported revenue of $4.21 billion, up 19.3% over the same period last year. EPS came in at $0.63, compared to $0.50 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $4.03 billion, representing a surprise of +4.35%. The company delivered an EPS surprise of +8.62%, with the consensus EPS estimate being $0.58.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall ...

Boston Scientific (BSX) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.58 per share. This compares to earnings of $0.50 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 8.62%. A quarter ago, it was expected that this medical device manufacturer would post earnings of $0.58 per share when it actually produced earnings of $0.62, delivering a surprise of 6.90%.Over the last four qua ...

Boston Scientific Announces Results for Third Quarter 2024 Marlborough, Mass. (October 23, 2024) -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.209 billion during the third quarter of 2024, growing 19.4 percent on a reported basis, 19.5 percent on an operational basis and 18.2 percent on an organic basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $469 million or $0.32 per share (EPS), compared ...

UKRAINE - 2021/06/17: In this photo illustration, a Boston Scientific Corporation logo seen ... [+] displayed on a smartphone and pc screen in the background. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesBoston Scientific (NYSE: BSX) is scheduled to report its Q3 2024 results on Wednesday, October 23. We expect the company to report revenues and earnings slightly below the consensus estimates. The company should continue to benefit fr ...

New FARAWAVE™ NAV Ablation Catheter and FARAVIEW™ Software combine with OPAL HDx™ Mapping System to provide visualization during pulsed field ablationMARLBOROUGH, Mass., Oct. 18, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the navigation-enabled FARAWAVE™ NAV Ablation Catheter for the treatment of paroxysmal atrial fibrillation (AF) and FDA 510(k) clearance for the new FARAVIEW™ Software, which will combi ...

The upcoming report from Boston Scientific (BSX) is expected to reveal quarterly earnings of $0.58 per share, indicating an increase of 16% compared to the year-ago period. Analysts forecast revenues of $4.03 billion, representing an increase of 14.4% year over year.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.2% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Before a co ...